Moderna Aktie

143,10USD -0,60USD -0,42%
Moderna für 0 Euro bei ZERO ordern (zzgl. Spreads)
WKN DE: A2N9D9 / ISIN: US60770K1079
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Aktionärsstruktur

Inhaber in %
Freefloat 87,87
Baillie Gifford & Co. 11,92
Baillie Gifford & Co. 11,66
The Vanguard Group, Inc. 10,20
Vanguard Group, Inc. (Subfiler) 9,83
Stéphane Bancel, MBA 5,50
State Street Corp. 3,77
Vanguard Total Stock Market ETF 2,82
Fidelity Management & Research Co. LLC 2,64
BlackRock Fund Advisors 2,62
Flagship Ventures Management, Inc. 2,52
Scottish Mortgage Investment Trust Plc 2,40
Vanguard International Growth Fund 2,39
Vanguard 500 Index Fund 2,20
Vanguard Mid Cap Index Fund 1,95

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2019 2020 2021 2022 2023
Personal am Ende des Jahres 830 1 300 2 700 3 900 5 600
Umsatz pro Mitarbeiter in Mio. EUR 0,07 0,62 6,82 4,90 1,22

Bilanz (in Mio. EUR) - Aktiva

2019 2020 2021 2022 2023
Summe Umlaufvermögen 1 129 6 298 16 071 13 431 10 325
Summe Anlagevermögen 1 311 2 799 15 061 20 323 15 097
Summe Aktiva 1 589 7 337 24 869 26 087 18 426

Bilanz (in Mio. EUR) - Passiva

2019 2020 2021 2022 2023
Gesamtverschuldung/ -verbindlichkeiten 136 238 916 1 200 1 243
Summe Fremdkapital 415 4 775 10 724 6 964 4 572
Summe Eigenkapital 1 175 2 561 14 145 19 123 13 854
Summe Passiva 1 589 7 337 24 869 26 087 18 426

Adresse

325 Binney Street, 02142 Cambridge
Telefon +1 (617) 714-6500
Internet http://www.modernatx.com

Management

Brad Miller
Chief Information Officer
Charbel Haber
Senior Vice President-Regulatory Affairs
Elizabeth E. Tallett
Independent Director
Elizabeth G. Nabel
Independent Director
Francois Nader
Independent Non-Executive Director
Jacqueline Miller
Senior VP-Infectious Disease Development
James M. Mock
Chief Financial Officer
Jerh Collins
Chief Technical Operations & Quality Officer
John Lepore
Senior Vice President-Government Engagement
Jonathan Hoggatt
Director-Hematology
José M. Vega
Chief Safety Officer
Kate Cronin
Chief Brand Officer
Lavina A. Talukdar
Senior Vice President & Head-Investor Relations
Melanie Ivarsson
Chief Development Officer
Noubar B. Afeyan
Chairman
Patrick Norman Bergstedt
Senior Vice President-Commercial Vaccines
Paul L. Sagan
Independent Non-Executive Director
Paula Hammond
Scientific Advisory Board
Robert S. Langer
Independent Non-Executive Director
Sandra J. Horning
Independent Director
Shannon Thyme Klinger
Secretary & Chief Legal Officer
Stephen A. Berenson
Independent Non-Executive Director
Stephen Hoge
President
Stéphane Bancel
Chief Executive Officer & Director
Tracey Franklin
Chief Human Resources Officer